EI
VIVO

EAM Investors’s Meridian Bioscience Inc VIVO Stock Holding History

EAM Investors’s Portfolio VIVO Stock Details VIVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-96,610
Closed -$2.94M – 374
2022
Q2 		$2.94M Buy
+96,610
New +$2.61M 0.72% 17
2020
Q3 		– Sell
-98,678
Closed -$2.3M – 377
2020
Q2 		$2.3M Buy
+98,678
New +$1.43M 0.51% 54

Other funds holding VIVO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Impactive Capital New York City, New York $1.38B AUM 1.92% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EAM Investors's VIVO Position: Q3 2022 in Review

EAM Investors sold out of Meridian Bioscience Inc (VIVO) in Q3 2022, closing a stake of 96,610 shares — an estimated $2.94M sold.

EAM Investors first reported a position in VIVO in Q2 2020 and held it in 2 quarters. The position peaked at $2.94M in Q2 2022. 203 funds tracked by Wall St. Rank hold VIVO as of Q3 2022.

  • EAM Investors reported no remaining Meridian Bioscience Inc position as of Q3 2022 after selling out during the quarter.
  • EAM Investors sold 96,610 Meridian Bioscience Inc shares in Q3 2022, an estimated $2.94M.
  • EAM Investors first reported a position in Meridian Bioscience Inc in Q2 2020 and held it in 2 quarters.
  • EAM Investors's Meridian Bioscience Inc position peaked at $2.94M in Q2 2022.
  • 203 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q3 2022.

Based on EAM Investors's 13F filing for Q3 2022, filed 14 Nov 2022.